Table 1. Patient Characteristics.
| Characteristic | Number of Patients | % |
|---|---|---|
|
| ||
| Total number of patients | 22 enrolled | |
| 20 vaccinated | ||
| 20 evaluable | ||
|
| ||
| Age, years | ||
| Median | 52 | |
| Range | 34-69 | |
|
| ||
| ER-positive or PR-positive tumor | 13 | 65 |
|
| ||
| HER-2-positive tumor | 20 | 100 |
|
| ||
| Metastatic disease at diagnosis | 7 | 35 |
|
| ||
| DFI to relapse (months)* | ||
| Mean | 32 | |
| Median | 28 | |
| Range | 0-130 | |
|
| ||
| Sites of distant metastasis | ||
| Bone | 14 | 70 |
| Liver | 5 | 25 |
| Lung | 4 | 20 |
| Lymph node (distant) | 3 | 15 |
| Brain | 1 | 5 |
|
| ||
| Sum of the longest tumor diameter at study entry |
||
| Mean | 40.7 mm | |
| Median | 24.5 mm | |
|
| ||
| Prior lines of chemotherapy for metastatic disease |
||
| Median | 1 | |
| Range | 0-6 | |
| Mean | 1.25 | |
|
| ||
| Prior trastuzumab therapy | ||
| Adjuvant | 3 | 15 |
| Metastatic | 18 | 90 |
|
| ||
| Prior lapatinib therapy | 2 | 10 |
|
| ||
| Concurrent endocrine therapy | 11 | 55 |
|
| ||
| Concurrent bisphosphonate therapy | 14 | 70 |
Abbreviations: ER=estrogen receptor; PR=progesterone receptor; HER-2=human epidermal growth factor receptor-2; DFI=disease-free interval
*
13 patients who did not present with metastatic disease at diagnosis